HEC169096 in Participants With Advanced Solid Tumors
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 456
- Registration Number
- NCT05451602
- Locations
- 🇨🇳
GuangDong Province Peoples Hospital, Guangzhou, China
ADME Study of [14C] Antaitavir Hasophate in Healthy Male Subjects
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT05446233
- Locations
- 🇨🇳
Shanghai xuhui central hospital, Shanghai, Shanghai, China
A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate Liver Damage
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: pyroglutamate rongliflozin capsules
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05427682
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT05397379
- Locations
- 🇨🇳
Hunan Provincial People's Hospital, Changsha, Hunan, China
🇨🇳NanFang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Union Hospital, TongJi Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei, China
Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C
- Conditions
- Chronic HCV Infection
- Interventions
- Drug: HEC74647PA+HEC110114Drug: Placebo
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 514
- Registration Number
- NCT05395416
- Locations
- 🇨🇳
Hainan Provincial People's Hospital, Haikou, Hainan, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The Second Hospital of Anhui Medical University, Hefei, Anhui, China
Evaluation Freethiadine Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: Freethiadine tablets (part II)Drug: Freethiadine tablets(part I)Drug: Freethiadine placebo tablets
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT05391360
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳Southern Hospital of Southern Medical University, Guangzhou, Guangdong, China
To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT05383131
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal Impairment
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: pyroglutamate rongliflozin capsules
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05374343
- Locations
- 🇨🇳
Ping Feng, Chendu, Sichuan, China
A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT05294536
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
- Conditions
- Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT05139719
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China